http://rdf.ncbi.nlm.nih.gov/pubchem/patent/KR-20150130669-A
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_2b4be2300a741a69aa1b8bb47a88899f |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-3955 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K48-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N15-11 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K48-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-395 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P31-12 |
| filingDate | 2014-05-14^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_2df335f7df7e8ebe80dba084631a2264 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_361d962a0f8878ec71f4576c056be842 |
| publicationDate | 2015-11-24^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | KR-20150130669-A |
| titleOfInvention | Pharmaceutical composition for prevention and treatment for Hepatitis C containing Abi1 expression or activity inhibitor |
| abstract | The present invention relates to a pharmaceutical composition for the prevention and treatment of hepatitis C, and more particularly to a composition comprising Abi1 (Abelson interactor 1) expression or activity inhibitor. The inventors of the present invention have identified cell proteins that interact with the HCV NS5A protein using protein microarray technology and have identified about 90 cell proteins that interact with HCV NS5A. Of these NS5A partners, Abi1 was chosen. The binding of HCV NS5A to Abi1 was demonstrated using in vitro pull down and common precipitation assays. Abi1 is essential for HCV replication. In addition, EGF-stimulated Erk and Egr1 activation was inhibited by NS5A, and this inhibitory effect was mediated by the Abi1 protein. Abi1 expression knockdown impaired HCV replication, whereas Abi1 overexpression increased HCV proliferation. Taken together, these results support the hypothesis that HCV inhibits the MEK / ERK signaling pathway for its own proliferation by forcing Abi1 in host cells. Therefore, a substance that inhibits Abi1 activity or expression is useful as a preventive and therapeutic agent for hepatitis C by inhibiting proliferation of HCV. |
| isCitedBy | http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-109557198-A |
| priorityDate | 2014-05-14^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Showing number of triples: 1 to 377 of 377.